About 6 cents atm for flea farts of RDGL is what one should expect after an offering for more than 5% of company at $0.078. That combined with RDGL being an FDA play still messing with animals, makes about 6 cents a fair price vs. the risk. In short, everything about RDGL is moot without IDE approval for human trials, and at moment, there's no end in sight to RDGL getting around to submitting an IDE application for FDA consideration..
Getting on 21 months now since MK said RDGL would submit Radiogel IDE application, and here we are still waiting. Sure wish the guy would focus.
Market Data 
Markets 
AI
